Biotech Business - March 29, 2023
Evaxion announces increased focus and fast-tracking of its new AI discovery to patients
The company has announced an increased focus on its strategy around its core AI capabilities allowing fast and de-risked development of its pipeline. Recently, Evaxion announced that the company has used its AI technology to discover a new treatment opportunity that may broaden cancer immunotherapy. Through new cancer targets, so-called ERVs (endogenous retroviruses), it may […]
Biotech Business - March 28, 2023
Salipro publishes results from collaboration with AstraZeneca
The study describes a novel method to directly extract membrane proteins from cells into lipid Salipro nanoparticles, enabling structure-function analysis using surface plasmon resonance (SPR) and cryo-electron microscopy (cryo-EM) for challenging drug targets. For this study, the teams leveraged GeneArt Gene-to-Protein Services, part of Thermo Fisher Scientific, for protein production with structure determination support from […]
Biotech Business - March 28, 2023
Evaxion Biotech has developed a new AI platform technology
ObsERV identifies patient-specific virus targets, so-called ERVs (endogenous retroviruses), expressed in cancer. Evaxion has demonstrated that overexpression of such ERVs is strongly associated with the overall survival of cancer patients, notably of patients that are normally considered unresponsive to immunotherapy. In addition, the company has preclinically demonstrated complete tumor eradication in animal models when targeting […]
CDMO - March 23, 2023
Biovian and Remedium collaborate on AAV gene therapy
The agreement covers Remedium’s lead candidate, a disease-modifying treatment for Osteoarthritis (OA) under the name RMD 1101. Biovian has agreed to include Remedium’s lead candidate in Biovian’s AAV manufacturing platform development program. Biovian’s second-generation AAV platform will be built around a selected high-productivity and state-of-the-art quality suspension-based HEK293 cell line, with full scalability to 200L […]
Biotech Business - March 22, 2023
Aqilion to recieve 20.1 million SEK
In order to strengthen the company’s liquidity and to ensure the continued development of the company’s pipeline, on July 27, 2022 the Aqilion Board of Directors decided on to carry out an issue with priority for existing owners. The issue was carried out during the third quarter of 2022 as an issue of units, which […]
Agreement - March 7, 2023
Affibody and Chiesi Group collaborate
Affibody and Chiesi Group have announced the execution of a collaboration and licensing agreement to develop and commercialize innovative treatments for respiratory diseases using Affibody’s technology. Under the terms of the agreement, the parties will collaborate closely to progress up to three programs based on Affibody molecules against undisclosed targets for respiratory diseases. Chiesi will […]
